Kornimate/medical-research-clean huggingface dataset:
immunogenicity and safety of an inactivated sars-cov-2 vaccine coadministered with two attenuated vaccines

Conditions: SARS-CoV-2 Infection; Varicella; Measles; Mumps; Rubella

Summary: eligible participants were randomly assigned (1:1:1), using block randomization stratified, to either 3 groups. group 1 will be immunized inactivated sars-cov-2 vaccine and varicella vaccine in day 0 followed by measles-mumps-rubella vaccine(mmr) in day 28. group 2 will be immunized varicella vaccine in day 0 followed by sars-cov-2 vaccine and mmr in day 28. group 3 will be immunized inactivated sars-cov-2 vaccine in day 0 followed by mmr and varicella vaccine in day 28. vaccines were administered 28 days apart, with blood samples taken on day 0 and day 28 before vaccination, and on day 56. local and systemic symptoms and serious adverse events following immunzation were collected.


Eligibility criteria:
inclusion criteria: * aged 4 years old * with legal guardian signing the informed consent * able to participate in all planned visits and comply with all research procedures (such as completing diary cards of adverse events and participating visits) * with clear vaccination records including no sars-cov-2 vaccine history, with 1 varicella vaccine and 2 measles-containing vaccines history * the last attenuated vaccine was administered ≥28 days ago, and other vaccines administered ≥14 days ago * with an axillary temperature ≤37.5℃ at the time of vaccination exclusion criteria: first dose exclusion criteria: * with sars-cov-2 infection in the last 3 months (any of the following conditions shall be met: positive nucleic acid test; positive antigen test; suspected sars-cov-2 infection symptoms of subject or close contacts) * allergic to any substance of the vaccine or with a severe allergic reactions history of vaccines (such as acute allergic reactions, angioneurotic edema, breathing difficulties, etc.) * suffering uncontrolled epilepsy or progressive nerve system diseases, or with a history of gribali syndrome * with acute illness, severe or acute attack of chronic illness or fever * with immunodeficiency or weakened immune system or being treated with immunosuppressant drugs (oral steroids) * received non specific immunoglobulin within 3 months * any situation that researchers thought that might influence the consequence of the clinical trial second dose exclusion criteria： * occurrence of any serious adverse event that may be related to the previous dose of study vaccine * occurrence of systemic adverse reactions or allergic reactions with a severity level ≥ 3 recognized by researchers after vaccination * any new situations that fit the first dose exclusion criteria * any situation that researchers thought that might influence the consequence of the clinical trial

Keywords: inactivated sars-cov-2 vaccine coadministeration varicella vaccine measles, mumps and rubella combined vaccine
impact of pharmacists' training on oral anticoagulant counseling

Conditions: Deep Vein Thrombosis; Pulmonary Embolism; Atrial Fibrillation

Summary: this study evaluates the impact of community pharmacists' educational training on the nature and adequacy of counseling provided to patients on warfarin, an oral anticoagulant. half of the community pharmacists participating in the study will receive a two-week educational training on how to adequately counsel patients on warfarin while the other half of community pharmacists will receive the same training after the study. a mystery patient model will be used in this intervention study where six different trained and standardized individuals will act as patients. each of these mystery patients will supposedly have pulmonary embolism, deep vein thrombosis, or atrial fibrillation. the mystery patient will visit each pharmacy to buy warfarin or complain about adverse drug reaction been experienced. it is expected that pharmacists will provide relevant information and counseling to these patients on the use of the medication warfarin and how to handle the adverse drug reactions.

although direct oral anticoagulants also have their limitations (such as the risk of gastrointestinal bleeding) they are not as prominent as that of warfarin but still important to consider before prescribing to patients. these limitations associated with the use of oral anticoagulants prove that there is need for special counseling of patients placed on oral anticoagulants. counseling, as an important aspect of drug therapy management, is somewhat technical and requires a peculiar way of providing vital information on drug therapy within the shortest possible time. pharmacists, who are key members of the healthcare team, are tasked with this role more than others and as such this area is of optimum importance. proper and adequate counseling on oral anticoagulants is essential for optimal use of the drug and to reduce the number of incidence of adverse drug reactions. adequate counseling cannot be achieved without proper training. this aspect is seen to be lacking due to the suboptimal performance discovered in research among healthcare professionals including pharmacists with regards to counseling of patients on oral anticoagulant use mystery patients in pharmacy practice research are a very reliable means of obtaining unbiased data on pharmacists with regards to counseling. this study, therefore, is aimed at providing counseling training to community pharmacists and evaluating the impact of the training on patients indirectly using the mystery patient model.

Eligibility criteria:
inclusion criteria: * community pharmacists with at least one-year practice experience * community pharmacies that stock and dispense warfarin exclusion criteria: * community pharmacists working in order sectors

Keywords: patient counseling mystery patient oral anticoagulant pharmacist warfarin adverse drug reaction nigeria community pharmacists
efficacy and safety of rivaroxiban compare with vitamin k antagonist warfarin

Conditions: Mitral Valve Stenosis; Atrial Fibrillation

Summary: title: efficacy and safety of rivaroxiban compare with vitamin k antagonist warfarin in patients with atrial fibrillation and mitral stenosis among pakistani population.

atrial fibrillation is associated with an increase in the risk of ischemic stroke by a factor of four to five and accounts for up to 15% of strokes in persons of all ages and 30% in persons over the age of 80 years. the use of vitamin k antagonists is highly effective for stroke prevention in patients with non-valvular atrial fibrillation and is recommended for persons at increased risk. however, food and drug interactions necessitate frequent coagulation monitoring and dose adjustments, requirements that make it difficult for many patients to use such drugs in clinical practice. rivaroxaban is a direct factor xa inhibitor that may provide more consistent and predictable anticoagulation than warfarin. it has been reported to prevent venous thromboembolism more effectively than enoxaparin in patients undergoing orthopedic surgery and was non-inferior to enoxaparin followed by warfarin in a study involving patients with established venous thrombosis. this trial was designed to compare once-daily oral rivaroxaban with dose-adjusted warfarin for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation who were at moderate-to-high risk for stroke

Eligibility criteria:
inclusion criteria: * both gender * age from 18 years up to 55 years * rheumatic ms (mild moderate severe) hemodynamic ally stable patients * associated af or flutter documented on ecg * post ptmc or m com * not previously enrolled in any trial or study on noacs * willing to participate exclusion criteria: * rheumatic valve other than ms * prosthetic mitral valve surgery * previous tia or stroke * plan for valve replacement within six months * pregnancy * history of bleeding complication * high risk of bleeding complication * allergic to study drug * anemia (hb less than 10 g/dl) * raised sgpt \> 2xunl * creatinine clearance \<30ml/min * not willing to participate.
hand driven versus motor driven hysteroscopic tissue removal system for polypectomy: long-term results

Conditions: Endometrial Polyp

Summary: in this study, a comparison is made between two types of polyp resection methods (hand driven and motor driven morcellation). more specifically, the effects of the resection on symptoms such as abnormal uterine bleeding, and on the recurrence of polyps. the aim of the study is to find a superior method in terms of symptom relieve and polyp recurrence so this method can be used in gynaecological practice.

* rationale: several techniques for hysteroscopic removal of intrauterine polyps exist today. hysteroscopic morcellation is an effective, fast, and safe method for this. however, the differences between two different systems of hysteroscopic morcellation, motor-driven (truclear incisor mini device) and hand-driven (resectr 9fr) morcellation, are still unclear. the remove9 study, in which women with a polyp were randomized between both techniques, is currently investigating the differences in short-term effectiveness between the two techniques. * research question/goal: to investigate the long-term results of the effectiveness of a hysteroscopic morcellation of intrauterine polyps. the two systems are compared with each other. * study design: this is a prospective cohort study. the patients previously participated in a randomized controlled trial (remove9) and will now be contacted again for the completion of a one-time questionnaire. the study has an observational design. * study population: women with a history of endometrial polyp that was previously removed via hysteroscopic morcellation in the remove9 study. * primary and secondary endpoints: the primary endpoint is the risk of recurrence of abnormal uterine bleeding at post-surgery follow-up. secondary endpoints include recurrence of other symptoms, time to recurrence, symptom relief, onset of new symptoms, onset of new polyp, satisfaction with regards to symptoms, satisfaction with regards to the treatment in general, need for additional treatments for blood loss and occurrence of pregnancy (in subfertility group).

Eligibility criteria:
inclusion criteria: * participation in earlier study exclusion criteria: * n/a
mirror therapy in stroke

Conditions: Stroke; Cognitive Therapy; Telerehabilitation

Summary: little is known about mirror therapy and cognitive exercises applied together in patients with stroke by means of telerehabilitation. the aim of this study is to investigate the effects of home-based mirror therapy combined with cognitive exercises on upper extremity functions and cognition in adults with stroke and to compare these effects with mirror therapy alone.


Eligibility criteria:
inclusion criteria: age 40 years old and over having had a stroke having unilateral involvement having sufficient communication skills to answer oral and written questions and following instructions 20\< points in mmse exclusion criteria: a stroke history under the age of 40 not having a verbal or written communication level that cannot fulfill the study conditions
effects of a short-term aerobic interval exercise program on cardiac fat and function in women with obesity: a pilot study

Conditions: Obesity

Summary: the overall goal of this project is to the study the effects of an aerobic interval training program on cardiac fat, and its relationship to cardiac function using cardiac magnetic resonance imaging.


Eligibility criteria:
inclusion criteria: * females, age 18-40 years old, body mass index (bmi) ≥ 30 kg/m2 and \< 39.9 kg/m2, without known metabolic and/or cardiovascular disease exclusion criteria: * known cv, metabolic or pulmonary diseases or conditions, muscular-skeletal injuries (i.e. spine, knees, hips or shoulders, taking medications that affect endocrine or cardiovascular function, hypertension, being engaged in moderate intensity exercise more than two times per week or moderate-high intensity training of any type and frequency, being pregnant, cigarette smoking, having non-removable pieces or devices incompatible with dxa and cmr assessment

Keywords: cardiac fat cardiac function aerobic interval training cardiac magnetic resonance vascular health
a pharmacokinetic and tolerance study of oral ganciclovir in hiv-infected children with asymptomatic cytomegalovirus infection and low cd4 cell counts or quiescent cytomegalovirus disease

Conditions: Cytomegalovirus Infections; HIV Infections

Summary: primary: to determine the pharmacokinetics, mtd, and long-term safety and tolerance of oral ganciclovir in hiv-infected infants, children, and adolescents. secondary: to evaluate the effect of oral ganciclovir on the virologic parameters of cmv. maintenance treatment with intravenous (iv) ganciclovir for cytomegalovirus retinitis in aids patients is now standard therapy, but daily iv therapy can be complicated by catheter infections and thrombosis. an oral regimen of ganciclovir has been administered safely in adult aids patients and may be of significant benefit to children and infants as well.

maintenance treatment with intravenous (iv) ganciclovir for cytomegalovirus retinitis in aids patients is now standard therapy, but daily iv therapy can be complicated by catheter infections and thrombosis. an oral regimen of ganciclovir has been administered safely in adult aids patients and may be of significant benefit to children and infants as well. patients are assigned to 1 of 5 (per amendment 10/24/95, was 4) oral (syrup or capsules) dose levels following a single intravenous dose of ganciclovir. treatment continues for 72 (per amendment 10/24/95, was 24 weeks) weeks after the last patient has been enrolled.

Eligibility criteria:
inclusion criteria concurrent medication: per amendment 10/24/95: allowed: * all antiretroviral agents and other medications except those listed under exclusion - concurrent medications. * didanosine. however, patients receiving both drugs (didanosine and ganciclovir) should be monitored for toxicity. * amphotericin b is allowed but requires additional monitoring. patients must have: * hiv infection. * cmv infection. * cd4 count \< 150 cells/mm3 or \< 15 percent and/or quiescent cmv disease. * no loss of sight from cmv retinitis. * no acute opportunistic infection. * life expectancy at least to study completion. * consent of parent or guardian. note: * infants \ = 36 weeks gestational age at birth. note: * patients may co-enroll in other actg protocols that do not involve the administration of disallowed medications. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * loss of sight in one eye for any reason, with evidence of cmv retinitis in the other eye. * acute or chronic diarrhea that would affect absorption. * clinical or laboratory toxicities of grade 3 or worse. concurrent medication: excluded: * foscarnet. * acyclovir. * interferon. * myelotoxic agents for malignancy or other condition. * other agents with anti-cmv activity. (note: enrollment of patients on ivig must be discussed with protocol chair.) * imipenem/cilastatin sodium. prior medication: excluded within 30 days prior to study entry: * g-csf or gm-csf.

Keywords: ganciclovir cytomegalovirus infections acquired immunodeficiency syndrome
sleep disorders in transient ischemic attack and stroke: somn'aic study

Conditions: Sleep Disorder; Stroke

Summary: sleep disorders in the setting of stroke are numerous, including sleep-related breathing disorders, insomnia, excessive daytime sleepiness and restless legs syndrome. consequences of theses sleep disturbances include impaired functional outcome and quality of life, anxious and depressive troubles and increased cardio-vascular morbi-mortality. mechanisms underlying sleep disorders in the setting of stroke are complex and still partly elucidated. they probably involve the consequences of the ischemic lesion and of the handicap, but also of associated vascular risk factors and more generally pre-existent medical history, or they could represent themselves a risk factor for stroke. transient ischemic attack (tia) is a particular condition in which risk factors and background of patients are similar to that observed in stroke, without any cerebral lesion and no persistent neurological deficit. the main objective of the somn'aic study is to compare the prevalence of sleep disorders in stroke and in transient ischemic attack (tia). the study hypothesis is that the prevalence of sleep disorders may be higher in stroke than in tia patients, reflecting the consequences of the lesion and the associated handicap.


Eligibility criteria:
inclusion criteria: * stroke group: patients with a diagnosis of stoke and seen at the routine post-stroke 3 month' rehabilitation examination * tia group: diagnosis of a tia by a stroke specialist at the "sos tia" examination * \> 18 years exclusion criteria: * refusal to participate * severe cognitive impairment leading to inability to fulfil questionnaires * for the tia group: presence of an ischemic lesion on ct scan or mri
assess veinplicity venous access device safety and effectiveness

Conditions: Phlebotomy

Summary: the purpose of this study was to examine the veinplicity device as an adjunctive iv cannulation tool in subjects with a history of difficult to access veins. the veinplicity device is intended to improve venous access rates in compromised patients by taking advantage of the increased circulation that results from provoked muscle stimulation. the study collected information about the device, intravenous access, user and patient perceptions for iv access, and any device or procedural complications or other adverse events. device use was examined with patients in both a prone and upright position.


Eligibility criteria:
inclusion criteria: * subject ≥ 18 years of age * subject with history of failed venous access, venipuncture, or iv cannula placement * subject agreed to required follow-up * subject provided written, informed consent exclusion criteria: * subject currently had compromised skin on either forearm or hand * subject currently on any blood thinning medication other than 81mg of aspirin * subject had been diagnosed with peripheral neuropathy, has had a complex fracture or surgery in the forearm, or has other condition that diminishes sensation in one or both arms, hands or fingers * subject had a demand type pacemaker or defibrillator * subject is female of child-bearing potential and had a positive urine pregnancy test * subject had a history of seizure, convulsions or epilepsy * subject had a known allergy to epsom salts * subject had any other condition that may affect the ability to complete study requirements
evaluation of saliva il-6 levels and periodontitis

Conditions: Periodontal Diseases

Summary: the aim of this study was to analyze the association between salivary il-6 levels in patients with periodontitis. furthermore, the objective was to determine if the periodontitis influenced salivary il-6 levels

forty-nine patients with periodontitis and 47 healthy subjects (hs) were enrolled in the present study. enrolled patients were examined and characterized for clinical and blood samples analysis, and salivary il-6 levels. the spearman correlation test and jonckheere-terpstra test were applied in order to assess the interdependence between salivary il-6 levels and clinical periodontal parameters.

Eligibility criteria:
inclusion criteria: * presence of at least 16 teeth * cp with a minimum of 40% of sites with a clinical attachment level (cal) ≥2mm and probing depth (pd) ≥4mm; * presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs * presence of ≥40% sites with bleeding on probing (bop) exclusion criteria: * intake of contraceptives * intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study * status of pregnancy or lactation * previous history of excessive drinking * allergy to local anaesthetic * intake of drugs that may potentially determine gingival hyperplasia such as hydantoin, nifedipine, cyclosporin a or similar drugs.
sci&u peer health coaching program for individuals newly discharged from inpatient rehabilitation

Conditions: Spinal Cord Injury

Summary: the goal of this clinical trial is to learn if the online program and web-based platform for delivery of self-management services to people with spinal cord injury (sci) called "sci \& u" can support transitions from hospital to the community after injury. specifically, can providing support from trained peer health coaches via the sci \& u web-based self-management program increase health self-management among those within two years of a spinal cord injury with a planned discharge to or living in the community with sci for less than two years in the province of british columbia, canada or the state of connecticut, united states. the main question it aims to answer is: • does the sci \& u web-based self-management program lower emotional distress and increase self-efficacy researchers will compare those who participate in sci \& u with those who receive usual peer support after 6 months to see if the sci \& u program improves self-management knowledge, skills and self-efficacy and decreases secondary complications participants will: * engage in up to 14 online sessions, each of which lasts about an hour with a peer health coach trained in motivational interviewing, goal setting and brief action planning. during sessions, they may also review resources and create follow up plans on the online platform on health management topics * complete an interviewer administered survey at baseline, 6 and 12 months


Eligibility criteria:
inclusion criteria: * 18 years and older, with a planned discharge to or living in community with sci for no more than two years since injury and with the ability to speak and understand english exclusion criteria: * not a resident of british columbia or connecticut

Keywords: peer support self-management spinal cord injury newly injured web-based program